Effect of an Increase in Dose of Istradefylline, an A2A Receptor Antagonist, in Levodopa (LD)-Treated Patients with Parkinson’s Disease (PD)
Objective: To observe whether increasing the istradefylline dose from 20 to 40mg/day provides more patients with meaningful clinical responses. Background: Istradefylline, a well-tolerated selective adenosine…Design, characterization and In vivo evaluation of intranasal delivery of levodopa loaded microspere for Parkinsonism
Objective: Levodopa is the drug of choice in the treatment of Parkinson's disease but it exhibits low oral bioavailability and very low brain uptake. The…Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: a post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent rasagiline use (CRU). Background: OPC, a once-daily COMT inhibitor,…The Representativity of PSP patients included in clinical trials
Objective: To determine the representativity of patients with PSP eligible to clinical trials compared to consecutive PSP patients seen in a reference center and the…Multi-kinase Abelson (c-Abl) and Discoidin Domain Receptors (DDR1/2) inhibitors, Nilotinib, alters CSF soluble TREM2 (sTREM2) in individuals with Parkinson’s Disease
Objective: Our objective was to examine the effects of broad-based tyrosine kinase inhibition in cerebrospinal fluid biomarkers. Background: Nilotinib is a broad-based tyrosine kinase inhibitor…Management of Akinesia in Parkinson’s Disease with Apomorphine Subcutaneous Injection
Objective: To assess the effect of apomorphine on time-to-ON in PD patients with morning akinesia. Background: In patients with motor fluctuations complicating Parkinson's disease (PD), delays in time-to-ON…3 Year QoL Results for PD Patients Receiving DBS: Product Surveillance Registry
Objective: Summarize improvement in quality of life (QoL) by comparing scores from the EQ-5D questionnaire, five level response version (EQ-5D-5L) summary index and visual analog scale (EQ-VAS) obtained for…Dynamics of Device-based Treatments for Parkinson´s Disease in Germany from 2010 – 2017
Objective: Analyze the patient profiles and dynamics of utilization of Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa-carbidopa Intestinal Gel (LCIG), and Deep Brain Stimulation (DBS) for…A Case Presentation of Wilson’s Disease
Objective: To study clinical presentations of Wilson’s disease. Background: Wilson disease (WD; also known as hepatolenticular degeneration) is an autosomal-recessive disorder caused by mutation in…Abnormal Gait in Cerebrotendenious Xanthomatosis a case report
Objective: To identify patients with Cererotendenious xanthomatosis. To present the neurological spectrum of the disease. Background: Cerebrotendenious xanthomatosis is a rare lipid storage disease due…
- « Previous Page
- 1
- …
- 177
- 178
- 179
- 180
- 181
- …
- 217
- Next Page »